Pharma R&D has a reputation for glacial change, but AI could finally force the industry to pivot. According to Deloitte’s 2024 Global Life Sciences Sector Outlook released in late May, only about 16% of drug discovery efforts were using AI, though it projected triple-digit growth over the next few years. “It’s definitely early,” says AION…
R&D Market Pulse: Volvo/Daimler embrace digital alliance, VW restructures, Toyota bets on AI
The R&D World Index (RDWI) for the week ending November 1, 2024, closed at 3,855.65 for the 25 companies in the RDWI. The Index was down -2.70% (or -107.16 basis points). Eight RDWI members gained value last week from 0.16% (Alibaba) to 8.36% (AbbVie). Seventeen RDWI members lost value the previous from -0.43% (Cisco) to…
This week in R&D: GM and Hyundai to partner on vehicle development, Moderna cuts $1.1B in R&D spending, and Fed interest rate decision
The R&D World Index (RDWI) for the week ending September 13, 2024, closed at 3,924.01 for the 25 companies in the RDWI. The Index was up 2.95% (or 112.59 basis points). Seventeen RDWI members gained value last week from 0.30% (Volkswagen AG) to 14.26% (Oracle). Eight RDWI members lost value the previous week from -0.85%…
This week in R&D: Eli Lilly eyes $1,000 share price while pharma overall cuts back on R&D
The R&D World Index (RDWI) climbed 2.57% this week, with Eli Lilly leading the charge at a 10.84% gain, while tech giants ramp up AI investments amidst regulatory challenges. In the week ending August 9, 2024, the index closed at 3768.96 for the 25 companies in the RDWI. The index was up 2.57% (or 94.45…